Isolation, immortalization and characterization of human B lymphocytes for the development of diagnostic and therapeutic antibodies against cancer.

Isolation, immortalization and characterization of human B lymphocytes for the development of diagnostic and therapeutic antibodies against cancer. - Human antibodies against cancer.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47403

Enrollment

Registered

2013-04-11

Start date

2013-05-23

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-cancer antibodies / cancer eradication

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: o patients with a hematologic malignancy (leukemia or lymphoma) who received a hematopoetic stem cell transplantation and subsequently developed graft-versus-host disease and/or a sustained graft-versus-leukemia response; o patients with melanoma who showed spontaneous or treatment induced tumor regression, preferably in the presence of signs of auto-immunity , like vitiligo; o patients with gastrointestinal tumors (pancreatic or oesophagus) with either tumor regression or slower then expected tumor growth.

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

Measure	Time frame
The identification and production of tumor-specific monoclonal antibodies by the generation of tumor specific B lymphocyte clones.	—

Countries

Netherlands

Outcome results